›
^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:AVENIO Tumor Tissue CGP Kit
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
RocheType:
Laboratory Developed Test
Related tests:
The AVENIO Tumor Tissue CGP Kit is an in-house next-generation sequencing (NGS) research assay that provides comprehensive genomic profiling of solid tumors from formalin-fixed paraffin-embedded (FFPE) tissue samples. Designed to match the content of the 324 gene FoundationOne CDx panel, offering more insights and fewer missed opportunities than single biomarker or hot spot testing to help identify relevant alterations.
Cancer:
Solid Tumor
Gene:
ARID1A (AT-rich interaction domain 1A), BARD1 (BRCA1 Associated RING Domain 1), BCOR (BCL6 Corepressor), BRCA1 (Breast cancer 1, early onset), CCND3 (Cyclin D3), CDK4 (Cyclin-dependent kinase 4)
See More ...
ARID1A (AT-rich interaction domain 1A), BARD1 (BRCA1 Associated RING Domain 1), BCOR (BCL6 Corepressor), BRCA1 (Breast cancer 1, early onset), CCND3 (Cyclin D3), CDK4 (Cyclin-dependent kinase 4), CHEK2 (Checkpoint kinase 2), ERBB4 (erb-b2 receptor tyrosine kinase 4), FLT1 (Fms-related tyrosine kinase 1), FLT3 (Fms-related tyrosine kinase 3), FOXL2 (Forkhead Box L2), HER-2 (Human epidermal growth factor receptor 2), KDM5A (Lysine Demethylase 5A), MSH6 (MutS homolog 6), MUTYH (MutY homolog), NOTCH3 (Notch Receptor 3), NPM1 (Nucleophosmin 1), POLE (DNA Polymerase Epsilon)
Method:
Next-Generation Sequencing (NGS)